Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: Effect of emulsion formulations and surface modification

Lin, Ying; Tahara, Kohei; Takeuchi, Hirofumi

doi:10.1016/j.ijpharm.2013.06.024

Cited by 55 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are few commercial topical formulations specifically intended for the treatment of ocular posterior segment diseases. Even so, in recent years, new advanced topically drug release systems have been developed in order to improve the drug access to the back of the eye, such as nanoparticles [99,118], emulsions [119], nanostructured lipid carriers [120], liposomes [121], and nanosuspensions [122].…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

et al. 2020

View full text Add to dashboard Cite

The treatment of the posterior-segment ocular diseases, such as age-related eye diseases (AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the complex anatomy and physiology of the eye. This specialized organ is composed of various static and dynamic barriers that restrict drug delivery into the target site of action. Despite numerous efforts, effective intraocular drug delivery remains unresolved and, therefore, it is highly desirable to improve the current treatments of diseases affecting the posterior cavity. This review article gives an overview of pharmacokinetic and biopharmaceutics aspects for the most commonly-used ocular administration routes (intravitreal, topical, systemic, and periocular), including information of the absorption, distribution, and elimination, as well as the benefits and limitations of each one. This article also encompasses different conventional and novel drug delivery systems designed and developed to improve drug pharmacokinetics intended for the posterior ocular segment treatment.

show abstract

Section: Drug Delivery Systemsmentioning

confidence: 99%

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, physicochemical properties of LN such as particle size, surface and composition can significantly influence drug delivery on ocular delivery (Ying et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Fangueiro

Andreani

Egea

et al. 2014

International Journal of Pharmaceutics

128

View full text Add to dashboard Cite

a b s t r a c tIn the present study we have developed lipid nanoparticle (LN) dispersions based on a multiple emulsion technique for encapsulation of hydrophilic drugs or/and proteins by a full factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, a cationic lipid, namely cetyltrimethylammonium bromide (CTAB), was added in the lipid matrix of the optimal LN dispersion obtained from the factorial design. There are a limited number of studies reporting the ideal concentration of cationic agents in LN for drug delivery. This paper suggests that the choice of the concentration of a cationic agent is critical when formulating a safe and stable LN. CTAB was included in the lipid matrix of LN, testing four different concentrations (0.25%, 0.5%, 0.75%, or 1.0%wt) and how composition affects LN behavior regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. In order to develop a safe and compatible system for ocular delivery, CTAB-LN dispersions were exposed to Human retinoblastoma cell line Y-79. The toxicity testing of the CTAB-LN dispersions was a fundamental tool to find the best CTAB concentration for development of these cationic LN, which was found to be 0.5 wt% of CTAB.

show abstract

“…Pharmaceutics 2020, 12, 198 20 of 29 In the case of eye and brain, which according to the old immune-privileged concept are organs isolated and protected from the systemic immune response of the organism [119], the use of less immunogenic non-viral vectors [165] is even more relevant to avoid damage in such sensitive organs [43]. In addition, in order to develop a more friendly approach, at a preclinical level, many nanotechnology-based formulations of different materials, shapes, and compositions can be tailored with specific ligands to overcome both BRB and BBB and deliver their cargo by non-invasive routes of administration such as topical instillation on ocular [166][167][168][169] and nose surfaces [170][171][172] (Figure 8). Considering the versatility of the cationic niosome platform for gene delivery applications, some of the biomaterials commonly used to overcome the BRB and BBB, such as transferrin, Annexin V, insulin, or gemini surfactants, could be incorporated in novel niosome vesicles, bearing in mind the recent results reported after the in situ administration of such non-viral vectors in both retina and brain cortex tissues.…”

Section: Future Perspectivesmentioning

confidence: 99%

Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues

et al. 2020

View full text Add to dashboard Cite

Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components of niosome formulations include a cationic lipid that is responsible for the electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that enhances the long-term stability of the niosome, and a helper component that can be added to improve its physicochemical properties and biological performance. This review is aimed at providing recent information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will discuss the composition, preparation methods, physicochemical properties, and biological evaluation of niosomes and corresponding nioplexes that result from the addition of the genetic material onto their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally, as future perspectives, non-invasive administration routes and different targeting strategies will be discussed.

show abstract

Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: Effect of emulsion formulations and surface modification

Cited by 55 publications

References 27 publications

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues

Contact Info

Product

Resources

About